ESMO 2018 | Localized high-risk prostate cancer: updated results from 12-year follow up of GETUG-12

Name: Localized high-risk prostate cancer: updated results from 12-year follow up of GETUG-12
Uploaded: 2018-10-19T00:00:00.000Z
Duration: 1 min 17 s

Alison Birtle • 19 Oct 2018

ESMO 2018

Genitourinary Cancer Prostate Cancer Docetaxel Estramustine

GETUG-12

The updated results from the 12-year follow-up of the GETUG-12 (NCT00055731) study were presented at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Here, Alison Birtle, MD, of Royal Preston Hospital Lancashire Teaching Hospitals, Preston, UK, discusses this promising new data from the study, which investigated docetaxel and estramustine for high-risk localized prostate cancer. She highlights the fact that these data support that found in the UK-based STAMPEDE study (NCT00268476).